The Alpha-Emitter Radioligand Therapy market is poised for a decade of transformative growth. With a USD 1.23 billion valuation expected by 2032, the sector is moving beyond its "experimental" phase. The shift toward personalized medicine and the success of early-stage trials in hard-to-treat cancers suggest that alpha-emitters will soon become a first-line treatment option, rather th... https://www.databridgemarketresearch.com/reports/global-alpha-emitter-radioligand-therapy-market